Analyst Price Targets — INO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 13, 2026 9:01 am | — | Jefferies | $3.00 | $0.90 | TheFly | Inovio upgraded to Buy from Hold at Jefferies |
| June 1, 2026 10:11 am | — | H.C. Wainwright | $2.50 | $1.31 | TheFly | Inovio price target lowered to $2.50 from $3 at H.C. Wainwright |
| November 14, 2025 1:11 pm | Edward Tenthoff | Piper Sandler | $6.00 | $1.99 | StreetInsider | 'Inovio Pharmaceuticals (INO) Raises $28.75M to Fund Operations'; PT Raised at Piper Sandler |
| August 9, 2024 6:26 am | Gregory Renza | RBC Capital | $8.00 | $8.71 | StreetInsider | Inovio Pharmaceuticals (INO) PT Lowered to $8 at RBC Capital |
| May 14, 2024 10:08 am | Hartaj Singh | Oppenheimer | $40.00 | $11.45 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Inovio Pharmaceuticals (INO) |
| May 13, 2024 4:32 pm | Sudan Loganathan | Stephens | $20.00 | $11.36 | TheFly | Inovio initiated with an Overweight at Stephens |
| January 25, 2024 6:57 am | Hartaj Singh | Oppenheimer | $4.00 | $6.79 | StreetInsider | Oppenheimer Upgrades Inovio Pharmaceuticals (INO) to Outperform |
Latest News for INO
PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Cantor Global Healthcare Conference (New York) Date: Wednesday, September 9 Fireside Chat:…
Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues preparations for a potential commercial launch.
Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript
U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial preparations advancing in anticipation of potential product launch for INO-3107 Positive topline results reported from Phase 3 trial for VGX-3100 for the…
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.